|1.||Miyamoto, Shingo: 11 articles (08/2015 - 08/2004)|
|2.||Yotsumoto, Fusanori: 10 articles (08/2015 - 05/2006)|
|3.||Kuroki, Masahide: 8 articles (08/2015 - 11/2007)|
|4.||Mekada, Eisuke: 6 articles (05/2015 - 08/2004)|
|5.||Yagi, Hiroshi: 5 articles (03/2009 - 08/2004)|
|6.||Li, Meng: 4 articles (11/2014 - 09/2011)|
|7.||Rappuoli, Rino: 4 articles (03/2010 - 02/2004)|
|8.||Deng, Suo: 3 articles (11/2014 - 06/2012)|
|9.||Tsujioka, Hiroshi: 3 articles (07/2011 - 08/2010)|
|10.||Sesardic, Dorothea: 3 articles (04/2008 - 09/2002)|
08/01/2015 - "CRM197 also inhibits the growth, migration, invasion, and induces apoptosis in various tumors. "
07/01/2014 - "In animal experiment, four groups of cells were inoculated to BALB/c nude mouse subcutaneously to observe tumor formation ability following CRM197 treatment. "
06/01/2012 - "Also, the coadministration of CDDP and CRM197 at 1 mg/kg/day completely inhibited tumor formation. "
06/01/2012 - "Further, tumor growth in xenografted mice was suppressed by CRM197 or CDDP at 1 mg/kg/day. "
06/01/2012 - "CRM197 and/or CDDP were injected intraperitoneally into tumor-bearing mice, and tumor volume was measured over time. "
06/15/2012 - "However, the effect of CRM197 on the resistant ovarian carcinoma cells has not been sufficiently elucidated. "
09/01/2011 - "This indicates that CRM197 may be an innovative intramolecular adjuvant and provides a rational preservation for mouse CT26 colon carcinoma."
02/01/2011 - "Enhanced inhibition of murine prostatic carcinoma growth by immunization with or administration of viable human umbilical vein endothelial cells and CRM197."
02/01/2011 - "Treatment with CRM197 in combination with viable HUVECs resulted in a marked enhancement of the antitumor effect in the preventive or therapeutic treatment for prostatic carcinoma in vivo, suggesting a novel combination for anti-cancer therapy."
11/01/2014 - "Here, we report that CRM197 significantly reverses the resistance to cisplatin in cisplatin-resistant ovarian carcinoma cell line (A2780/CDDP). "
|3.||Mouth Neoplasms (Oral Cancer)
06/01/2012 - "In this study, we analyzed the antitumor effects of CRM197, which represent possible chemotherapeutic agents for oral cancer. "
06/01/2012 - "These results suggest that HB-EGF is a target for oral cancer and that CRM197 is effective in oral cancer therapy."
06/01/2012 - "Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer."
06/01/2012 - "CRM197, a nontoxic mutant of diphtheria toxin, is a specific inhibitor of heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF), which belongs to the EGF family that has been implicated in the increased progression, proliferation, and metastasis of oral cancer. "
07/01/1997 - "Immunity to Haemophilus influenzae type b after reimmunization with oligosaccharide CRM197 conjugate vaccine in children with human immunodeficiency virus infection."
03/01/1996 - "Immunity to Haemophilus influenzae type b polysaccharide capsule after vaccination with the complete series of oligosaccharide CRM197 conjugate vaccine in infants with human immunodeficiency virus infection."
05/01/1990 - "These results suggest that conjugation of Hib polysaccharide with diphtheria CRM197 overcomes the defective antibody response to Hib oligosaccharide in children who are initially observed with recurrent infections and inability to respond to the Hib polysaccharide vaccine."
03/19/2010 - "A laminarin-diphtheria toxoid (CRM197) conjugate vaccine conferred protection against fungal infections in mice. "
06/10/1999 - "We prospectively determined the impact of immunization with 23-valent pneumococcal vaccine (PVAX) and Haemophilus influenzae type b (Hib)-modified diphtheria toxoid CRM197 (DT) vaccine on HIV-1 replication in recent HIV-1 seroconverters (n = 14; median, 5.5 months from infection; median CD4+ T cells, 535 microl), and correlated results with vaccine-related immune activation. "
05/01/2012 - "Patients demonstrated below normal responses to the diphtheria conjugate protein CRM197, a component of the pneumococcal vaccine. "
04/15/2010 - "Lymphocyte proliferative responses (LPRs) and T(H)1 cytokine T cell responses against the diphtheria-derived carrier protein CRM(197) contained in the PCV were investigated at weeks 0, 4, and 24. "
04/15/2010 - "CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated. "
04/01/2008 - "These findings highlight the promising prospect of using booster administrations of CRM(197) via the transcutaneous route to establish good herd immunity against diphtheria."
11/01/2002 - "A total of 500 infants from Soweto were immunized at 6, 10 and 14 weeks of age with either placebo (n = 250) or 9-valent pneumococcal conjugate vaccine (n = 250) containing serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F conjugated to CRM(197) mutant diphtheria protein. "
|1.||heparin-binding EGF-like growth factor (HB-EGF)
|2.||Diphtheria Toxoid (Vaccine, Diphtheria)
|4.||CRM197 (non-toxic variant of diphtheria toxin)
|6.||Tetanus Toxoid (Vaccine, Tetanus)
|2.||Heterologous Transplantation (Xenotransplantation)